

1615




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: CELAL ALBAYRAK.	Examiner: Unknown
Serial No. 10/506,952	Group Art Unit 1615
Filed: SEPTEMBER 8, 2004	Docket No. ABS0006/US
For: MICROPARTICLES AND METHOD FOR THEIR PRODUCTION	

Mail Stop: M Correspondence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I CERTIFY THAT ON NOVEMBER 15, 2006, THIS PAPER IS BEING
DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL
IN AN ENVELOPE ADDRESSED: COMMISSIONER FOR PATENTS,
P.O. Box 1450, ALEXANDRIA, VA 22313-1450.

Mary C. Deutsch

TRANSMITTAL LETTER

Dear Sir:

Enclosed for filing are the following papers in connection with the above-identified patent application:


1. Revocation of Power of Attorney and Appointment of New Power of Attorney and Change of Correspondence Address (1 pg)
2. Statement Under 37 CFR §3.73(b) (3 pgs)
3. Small Business Concern Small Entity Status Statement (2 pgs)
4. Return Receipt Postcard

No fee is believed to be necessary. Should any fee be required, the Commissioner is authorized to charge our Deposit Account No. 50-1775 and notify us of the same.

Dated: November 15, 2006

Respectfully Submitted,

By:


Dale A. Bjorkman #33,084
Customer No. 33072
Phone: 651-275-9811
Fax: 651-351-2954



G 134003

Revocation of Power of Attorney and Appointment of New Power of Attorney	Serial No.	10/506,952
	Filing Date	SEPTEMBER 8, 2004
	First Named Inventor	CELAL ALBAYRAK
	Title	MICROPARTICLES AND METHOD FOR THEIR PRODUCTION
	Examiner	Unknown
	Group Art	1615
Attorney Docket No.		ABS0006/US

I hereby revoke all previous powers of attorney given in the above-identified application:

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners at Customer Number:

33072

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number:

OR

33072

☐ I hereby appoint the following practitioners:

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71. Statement under
37 CFR 3.73(b) is enclosed.

SIGNATURE of Applicant or Assignee of Record

Name	Dr. Celal Albayrak		
Signature			
Date	October 17, 2006	Telephone	+49 (0)30-94 8924 83

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representatives are required. Submit Multiple forms if more than one signature is required.

☒

Total of 1 form(s) are submitted.



ABS0006/US

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Alrise Biosystems GmbH

Application No./Patent No./Control No.: 10/506,952

Filed/Issue Date: September 8, 2004

Entitled: **MICROPARTICLES AND METHOD FOR THEIR PRODUCTION**

Alrise Biosystems GmbH, a corporation

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a true copy of the original assignment is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:


1. From: Celal Albayrak To: Nektar Therapeutics (copy attached)
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: Nektar Therapeutics To: Alrise Biosystems GmbH (copy attached)
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


Signature

DR. CELAL ALBAYRAK
Print or Type Name

CEO
Title

October 17, 2006
Date

+49 (0)30-94892483
Telephone Number

ASSIGNMENT OF PATENT RIGHTS

Nektar Therapeutics, a corporation organized and existing under the laws of Delaware having a place of business at 150 Industrial Road, San Carlos, California 94070 (hereinafter called "Assignor"), hereby assigns certain patent rights to Alrise Biosystems GmbH, a corporation organized and existing under the laws of Germany having a place of business at Marienstraße 13; 10117 Berlin (hereinafter called the "Assignee"):

WHEREAS Assignor is the owner of the following patent applications set forth on Exhibit A; and

WHEREAS Assignor has agreed with Assignee for the transfer to it of the whole right, title and interest in and to said applications, and inventions.

NOW THE ASSIGNMENT WITNESSETH that for good and valuable consideration, and sufficiency of which one hereby acknowledges, Assignor, as beneficial owner, hereby assigns and transfers to Assignee said inventions, said applications, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefore and thereon, and in any and all divisions, continuations, and continuations-in-part of said applications, or reissues or extensions of said Letters Patent, and all rights, privileges and advantages appertaining thereto, including any and all rights to damages, profits or recoveries of any nature for past infringement of said Letters Patent, and the payment of any and all maintenance fees, taxes, and the like, TO HOLD the same unto and to the use of Assignee, its successors and assigns absolutely during the residue of the respective terms for which the said Letters Patent were granted and during any such terms, and for any and all rights extending from said applications and reissues.

Executed at San Carlos California as of the 12 day of MAY, 2006.

Assignor: Nektar Therapeutics

Signature:

Michael B. Einschlag

State of CALIFORNIA
County of SAN MATEO

On 12 MAY, 2006, before me Karen J. Moir, Notary Public personally appeared Michael B. Einschlag personally known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person, executed the instrument.

WITNESS my hand and official seal.

Ka J Moir




EXHIBIT A

Kagan Binder, PLLC Ref. No.	Nektar Therapeutics Ref No.	Title	Country	Status	Appln. No.	Appln. Date	Grant No.	Grant Date
ABS0002/US	0077-00	PROCESS FOR PRODUCING POLYMERIC MICROPARTICLES AND MICROPARTICLES PRODUCED BY SAID PROCESS AND THE USE OF SUCH PARTICLES IN MEDICAL DIAGNOSIS	USA	Granted	08/913,312	14-Mar- 1996	6,468,506	22-Oct- 2002
ABS0003/US	0071-00	METHOD OF PRODUCING MORPHOLOGICALLY UNIFORM MICROCAPSULES AND MICROCAPSULES PRODUCED BY THIS METHOD	USA	Granted	09/068,471	30-Oct- 1996	6,294,204	25-Sep- 2001
ABS0003/US/2	0071-10	METHOD OF PRODUCING MORPHOLOGICALLY UNIFORM MICROCAPSULES AND MICROCAPSULES PRODUCED BY THIS METHOD	USA	Granted	09/886,504	21-Jun- 2001	6,572,894	03-Jun- 2003
ABS0005/P1	0081-PRO	INDUCED PHASE TRANSITION METHOD FOR THE PRODUCTION OF MICROPARTICLES	USA	Inactive	60/257,527	21-Dec- 2000		
ABS0005/P2	0081-PRO2	INDUCED PHASE TRANSITION METHOD FOR THE PRODUCTION OF MICROPARTICLES	USA	Inactive	60/300,021	21-Jun- 2001		
ABS0005/US	0081-01	INDUCED PHASE TRANSITION METHOD FOR THE PRODUCTION OF MICROPARTICLES CONTAINING HYDROPHOBIC ACTIVE AGENTS	USA	Granted	10/027,401	19-Dec- 2001	6,899,898	31- May- 2005
ABS0005/US/2	0081-02	INDUCED PHASE TRANSITION METHOD FOR THE PRODUCTION OF MICROPARTICLES CONTAINING HYDROPHILIC ACTIVE AGENTS	USA	Pending	10/028,258	19-Dec- 2001		
ABS0006/US	0155-00	MICROPARTICLES AND METHOD FOR THEIR PREPARATION	USA	Pending	10/506,952	08-Sep- 2004		

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: CELAL ALBAYRAK.	Examiner: Unknown
Serial No. 10/506,952	Group Art Unit 1615
Filed: SEPTEMBER 8, 2004	Docket No. ABS0006/US
For: MICROPARTICLES AND METHOD FOR THEIR PRODUCTION	

**SMALL BUSINESS CONCERN
SMALL ENTITY STATUS STATEMENT**

I am the owner or an official of the small business concern identified below, and am empowered to act on behalf of the concern.

I hereby declare that the small business concern is a manufacturing industry for purposes of determining small business status. The small business qualifies as a small business concern as defined in 37 CFR 1.27(a), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control both.

I hereby declare that rights under contract or law to the invention described in the above-referenced application have been conveyed to and remain with the small business concern. If the rights held by the small business concern are not exclusive, each individual, concern or organization having rights in the invention are listed below, and qualifies as person under 37 CFR 1.27(a)(1), or qualifies as a small business concern under 37 CFR 1.27(a)(2) or a nonprofit organization under 37 CFR 1.27(c).

- ☒ No such person, concern or organization exists.
- ☐ Each such person, concern or organization is listed below. (NOTE: A separate small entity statement is required from each listed person, concern or organization)

I acknowledge the duty under 37 CFR 1.27(g)(1) to file, in this application, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Small Business Concern: Alrise Biosystems GmbH

Address of Small Business Concern: Robert-Rössle-Straße 10
Otto-Warburg-Haus (D80)
D-13125 Berlin

Name of Person Signing: CELAL ALBAYRAK

Title of Person Signing: CEO

Signature: 

August 29, 2006
Date